TrialPath
Recruiting

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

NCT07014293 · Massachusetts General Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
This is a randomized controlled trial assessing the effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency-Lymphoma (SMART3RP-Lymphoma) compared to Enhanced Usual Care on 254 early post treatment lymphoma survivors. The SMART-3RP is a comprehensive, evidence-based mind body group program designed to help individuals adapt to chronic stress (i.e., increase their resilience). It understands the adjustment to chronic stress as a dynamic process, blending CBT, positive psychology and mind body tools to target key coping processes. This trial seeks to answer the following questions: * Will survivors randomized to SMART3RP-Lymphoma demonstrate greater improvements in coping skills when compared to survivors randomized to enhanced usual care? * Do factors, such as age, sex, race/ethnicity, rural/urban living, socioeconomic status, impact how survivors respond to the treatment? Of note: This record describes our primary aim to compare the effects of SMART3RP-Lymphoma to enhanced usual care on lymphoma survivors' coping with the adjustment to posttreatment survivorship. While this trial will explore potential sociodemographic moderators of the main intervention effects on our primary aim (Aim 1), given the exploratory nature of these analyses (i.e., hypothesis-generating), we will not report the results of our moderation analyses in this record but rather focus on the main effects of the study intervention.
Eligibility criteria
Inclusion Criteria: * English speaking adult (18 years or older at enrollment) * At least 6-months post-lymphoma diagnosis and within 2 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy/immunotherapy/radiation therapy, or other) Exclusion Criteria: * Active Psychiatric or cognitive comorbidity as determined by site PI or treating clinician * Unwilling or unable to participate using telehealth platform
Study design
Enrollment target: 254 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2026-08-31
Estimated completion: 2030-07-01
Last updated: 2026-08-11
Interventions
Other: Enhanced Usual CareOther: SMART3RP-Lymphoma
Primary outcomes
  • Change from Baseline in Coping Scores on the Measure of Current Status Scale (MOCS-A) (Baseline to 3 month follow up)
Sponsor
Massachusetts General Hospital · other
All locations (1)
Mass General BrighamRecruiting
Boston, Massachusetts, United States
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors · TrialPath